| DB ID | MyCo_7071 |
| Title | Metabolomic profiling of exhaled breath condensate for the diagnosis of pulmonary aspergillosis |
| Year | 2022 |
| PMID | 36159648 |
| Fungal Diseases involved | Invasive pulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The study was conducted at Fujian Provincial Hospital in Southeast China. This study was approved by the Ethics Committees of Fujian Provincial Hospital (Ethical approval number K2021-03-041). Written informed consent was obtained from all suspected patients before the study started. |
| Site of Infection | Lungs |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Exhaled Breath Condensate (EBC) samples |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | Asperpyrone C |
| Biomarker Full Name | Asperpyrone C |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | China |
| Cohort | Between January 2018 and November 2019, A total of 133 patients were included in the study, including 66 PA patients (invasive pulmonary aspergillosis, n=3; chronic pulmonary aspergillosis, n=60; allergic bronchopulmonary aspergillosis, n=3) and controls (n=67). Ultra high-performance liquid chromatography coupled with high-resolution mass spectrometry(UHPLC-HRMS) was used to analyze EBC samples. Metabolic pro ling of EBC samples that were collected from 22 CPA patients at various times during treatment (before treatment, <1 month, 1–2 months, 2–3 months, 3–6 months, and ≥6 months after treatment initiation) were performed using UHPLC-HRMS. Potential biomarkers were evaluated using cluster analysis, Venn diagram and receiver operating characteristic analysis (ROC). |
| Cohort No. | 133 |
| Age Group | None |
| P Value | None |
| Sensitivity | 1 |
| Specificity | 0.896 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | The diagnosis of pulmonary aspergillosis (PA) remains a challenge. Currently, diagnosis is mainly based on routine testing, such as pathological evidence, culture and direct microscopic examination. However, these routine methods have poor sensitivities. Although bronchoalveolar lavage fluid (BALF) has been applied to galactomannan (GM) which is a component of the cell wall of Aspergillus assay and quantitative polymerase chain reaction (PCR) for diagnosis of PA and some progress has been made, the bronchoscopy examination is an invasive procedure and unsuitable for repeated use in practice. |
| Technique | Liquid chromatography |
| Analysis Method | Ultra high-performance liquid chromatography coupled with high resolution mass spectrometry(UHPLC-HRMS) |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Ultra high-performance liquid chromatography coupled with high resolution mass spectrometry(UHPLC-HRMS) |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
